AVITA Medical, Inc. — fact timeline

AVITA Medical, Inc. shareholders approved Approval of the Issuance of Equity Securities under ASX Listing Rule 7.1A at the 2026-06-04 meeting.

“10. Approval of the Issuance of Equity Securities (Proposal 15): Stockholders approved as a special resolution, for the purpose of ASX Listing Rule 7.1A (which allows the Company to seek stockholder approval to issue an additional 10% over the annual listing limit of 15% of its issued capital in a consecutive 12-month period) and all other purposes, the issue of Equity Securities (as defined in ASX Listing Rule 19.2) up to such additional 10% of the issued capital (at the time of issuance) of the Company (as calculated in accordance with ASX Listing Rule 7.1A.2). The votes regarding this proposal were as follows: Votes For Votes Against Abstentions Broker Non-Votes 8,947,195 2,223,106 531,604 3,890,542”

AVITA Medical, Inc. shareholders approved Approval of the Issuance of Warrants to Perceptive Credit Holdings V, LP at the 2026-06-04 meeting.

“9. Approval of the Issuance of Warrants (Proposal 14): Stockholders approved, for the purpose of ASX Listing Rule 7.1 (and all other purposes), the issuance of a warrant or warrants covering up to 650,000 shares of Common Stock, with a term of ten years (the “Warrants”), to Perceptive Credit Holdings V, LP (“Perceptive”), pursuant to the credit agreement between the Company and Perceptive, dated January 13, 2026. The votes regarding this proposal were as follows: Votes For Votes Against Abstentions Broker Non-Votes 9,322,532 1,769,627 609,746 3,890,542”

AVITA Medical, Inc. shareholders approved Advisory Vote on the Frequency of Future Advisory Votes on Executive Compensation at the 2026-06-04 meeting.

“8. Advisory Vote on the Frequency of Future Advisory Votes on Executive Compensation (Proposal 13) : Stockholders voted in favor of the non-binding advisory vote to set the frequency of future advisory votes to approve the compensation of the Company’s named executive officers. The votes regarding this proposal were as follows: Votes For 1 Year 2 Years 3 Years Abstentions Broker Non-Votes 9,545,151 924,743 650,252 581,759 3,890,542”

AVITA Medical, Inc. shareholders approved Advisory Vote to Approve Compensation of Named Executive Officers at the 2026-06-04 meeting.

“7. Advisory Vote to Approve Compensation of Named Executive Officers (Proposal 12) : Stockholders voted in favor of the non-binding advisory vote to approve the compensation of the Company’s named executive officers. The votes regarding this proposal were as follows: Votes For Votes Against Abstentions Broker Non-Votes 8,918,272 2,202,213 581,420 3,890,542”

AVITA Medical, Inc. shareholders approved Issuance of Securities to Joseph Woody (initial grant) at the 2026-06-04 meeting.

“6. Issuance of Securities to Joseph Woody (Proposal 10) : Stockholders approved the initial grant comprised of 40,547 restricted stock units and 29,446 stock options, to Mr. Joseph Woody, in accordance with the terms and conditions set out in the Proxy Statement. The votes regarding this proposal were as follows: Votes For Votes Against Abstentions Broker Non-Votes 8,863,312 2,395,376 443,217 3,890,542”

AVITA Medical, Inc. shareholders approved Issuance of Securities to Dr. Michael Tarnoff (initial grant) at the 2026-06-04 meeting.

“5. Issuance of Securities to Dr. Michael Tarnoff (Proposal 8) : Stockholders approved the initial grant comprised of 26,250 restricted stock units and 19,063 stock options, to Dr. Michael Tarnoff, in accordance with the terms and conditions set out in the Proxy Statement. The votes regarding this proposal were as follows: Votes For Votes Against Abstentions Broker Non-Votes 8,791,498 2,433,367 477,040 3,890,542”

AVITA Medical, Inc. shareholders approved Issuance of Securities to Non-Executive Directors (annual grants to each named director) at the 2026-06-04 meeting.

“4. Issuance of Securities to Non-Executive Directors (Proposals 4 - 7, 9 & 11) : Stockholders approved the annual grants comprised of 22,214 restricted stock units and 16,133 stock options, to each of the following non-executive directors, in accordance with the terms and conditions set out in the Proxy Statement. The votes regarding these proposals were as follows: Votes For Votes Against Abstentions Broker Non-Votes Professor Suzanne Crowe 8,869,562 2,411,009 421,334 3,890,542 Jeremy Curnock Cook 8,722,810 2,544,450 434,645 3,890,542 Robert McNamara 8,818,589 2,449,386 433,930 3,890,542 Jan Stern Reed 8,841,764 2,434,253 425,888 3,890,542 Dr. Michael Tarnoff 8,774,530 2,458,787 468,588 3,890,542 Joseph Woody 8,830,204 2,446,817 424,884 3,890,542”

AVITA Medical, Inc. shareholders approved Increase the maximum aggregate annual cash fee pool from which the non-executive Directors may be paid at the 2026-06-04 meeting.

“3. Increase the maximum aggregate annual cash fee pool from which the non-executive Directors of the Company may be paid (Proposal 3): Stockholders approved, for the purposes of ASX Listing Rule 10.17 and section 2.10 of the Company’s Amended and Restated Bylaws (and for all other purposes), an increase to the aggregate annual cash fee pool from which non-executive directors of the Company may be paid for their services from a maximum of US$750,000 per annum to a maximum of US$900,000 per annum. The votes regarding this proposal were as follows: Votes For Votes Against Abstentions Broker Non-Votes 8,582,602 2,710,656 408,647 3,890,542”

AVITA Medical, Inc. shareholders approved Ratification of the selection of Grant Thornton LLP as the Company’s independent registered public accounting firm at the 2026-06-04 meeting.

“2. Appointment of Independent Auditor (Proposal 2) : The stockholders ratified the selection of Grant Thornton LLP as the Company’s independent registered public accounting firm for the year ending December 31, 2026. The votes regarding this proposal were as follows: Votes For Votes Against Abstentions 14,962,654 255,151 374,642”

AVITA Medical, Inc. shareholders approved Election of Directors at the 2026-06-04 meeting.

“At the Annual Meeting, the Company’s stockholders voted on all the proposals summarized in the Proxy Statement, as set forth below: 1. Election of Directors (Proposal 1) : All seven directors named in the Proxy Statement were elected to serve on the Company’s Board of Directors with the following votes: Name Votes For Votes Withheld Broker Non-Votes Jan Stern Reed 10,902,991 798,914 3,890,542 Professor Suzanne Crowe 10,979,194 722,711 3,890,542 Jeremy Curnock Cook 10,700,424 1,001,481 3,890,542 Robert McNamara 10,962,888 739,017 3,890,542 Dr. Michael Tarnoff 11,011,908 689,997 3,890,542 Joseph Woody 10,977,874 724,031 3,890,542 Cary Vance 11,176,792 525,113 3,890,542”

AVITA Medical, Inc. reported first quarter ended March 31, 2026 results: revenue approximately $19.3 million, net income $10.6 million, EPS $0.35 per basic and diluted share. Guidance reaffirmed.

“today reported financial results for the first quarter ended March 31, 2026. First Quarter 2026 Financial Highlights and Recent Business Updates • Total revenue of approximately $19.3 million, up 4% year-over-year and approximately 10% sequentially, driven by contributions from Cohealyx ® and improved RECELL ® utilization as reimbursement dynamics normalize •”

Jan Stern Reed was appointed as Chair of the Board at AVITA Medical, Inc..

“the Board appointed Jan Stern Reed as Chair of the Board while simultaneously terminating the Lead Independent Director position that she had been serving since October 2025”

Cary Vance was appointed as President and Chief Executive Officer at AVITA Medical, Inc..

“the Board of Directors (the “Board”) of AVITA Medical, Inc (the "Company") appointed Cary Vance as President and Chief Executive Officer ("CEO"), effective April 30, 2026”

AVITA Medical, Inc. terminated Existing Credit Agreement with Lender under existing facility (effective 2026-01-13).

“Simultaneously with the closing of the Initial Commitment Amount, the Company repaid in full and terminated all of its obligations and commitments (the “Refinancing Transaction”) under the Existing Credit Agreement (as defined below).”

AVITA Medical, Inc. entered into Credit Agreement and Guaranty with Perceptive Credit Holdings V, LP valued at $60 million (effective 2026-01-13).

“On January 13, 2026 (the “Closing Date”), AVITA Medical, Inc. (the “Company”) entered into a Credit Agreement and Guaranty (the “Credit Agreement”) and a Security Agreement (the “Security Agreement”), by and among the Company, as borrower, Avita Medical Americas, LLC, a wholly-owned subsidiary of the Company, as guarantor (the “Guarantor,” taken together with the Company, the “Obligors”) and Perceptive Credit Holdings V, LP as a lender and the administrative agent (the “Lender,” and the “Administrative Agent,” as applicable).”

AVITA Medical, Inc. incurred credit facility of up to $60 million with Perceptive Credit Holdings V, LP at greater of (x) the SOFR rate for such period and (y) 4.00% plus, in either case, maturing five-year senior secured credit facility.

“Credit Agreement provides for a five-year senior secured credit facility in an aggregate principal amount of up to $60 million”

AVITA Medical, Inc.: Amended and restated bylaws to update stockholder meetings, electronic notice and other matters in respect of recent applicable law updates (effective 2025-05-15).

“Effective on the filing date of this Current Report on Form 8-K, the bylaws of AVITA Medical, Inc. were amended and restated in respect of recent updates to applicable law relating to conduct of stockholder meetings, electronic notice and other matters.”

Nicole Kelsey was appointed as Chief Legal and Compliance Officer and Corporate Secretary at AVITA Medical, Inc..

“Ms. Shiroma is succeeded by Nicole Kelsey, effective immediately, who will serve as the Company’s Chief Legal and Compliance Officer and Corporate Secretary.”

Donna Shiroma retired as General Counsel, Compliance Officer and Corporate Secretary at AVITA Medical, Inc..

“On June 28, 2024, Ms. Donna Shiroma, the Company’s General Counsel, Compliance Officer and Corporate Secretary, notified AVITA Medical, Inc. (the "Company") of her retirement effective immediately.”

AVITA Medical, Inc. updated its first quarter ended March 31, 2024 guidance (lowered).

“On May 13, 2024, AVITA Medical, Inc. issued a press release announcing its financial results for the first quarter ended March 31, 2024.”

AVITA Medical, Inc. reported first quarter of 2024 results: revenue US$11.0 million to US$11.3 million. Guidance lowered.

“previously provided guidance of US$78.5 million to US$84.5 million. For the quarter ended March 31, 2024, AVITA Medical now expects commercial revenue to be in the range of US$11.0 million to US$11.3 million. This range is below the previously provided revenue guidance of US$14.8 million to US$15.6 million. The revision in guidance is attributable to a”

AVITA Medical, Inc. reported full-year 2024 results: revenue Commercial revenue for the full-year 2024 is expected to be in the range of $78.5 to $84.5 million. Guidance initiated.

“Commercial revenue for the full-year 2024 is expected to be in the range of $78.5 to $84.5 million, reflecting growth of approximately 57% to approximately 69% over the full-year 2023”

AVITA Medical, Inc. reported first quarter 2024 results: revenue Commercial revenue for the first quarter 2024 is expected to be in the range of $14.8 to $15.6 million. Guidance initiated.

“Commercial revenue for the first quarter 2024 is expected to be in the range of $14.8 to $15.6 million, reflecting growth of approximately 42% to approximately 50% over the same period in the prior year”

AVITA Medical, Inc. reported Full-Year 2023 results: revenue Commercial revenue increased by 46% to $49.8 million, EPS Net loss for the full-year 2023 was $35.4 million, or a loss of $1.40 per basic and diluted share.

“50% to $14.1 million compared to the same period in 2022 • Gross profit margin of 87.3% Full-Year 2023 Financial Highlights • Commercial revenue increased approximately 46% to $49.8 million compared to the same period in 2022 • Gross profit margin of 84.5% • As of December 31, 2023, approximately $89.1 million in cash, cash equivalents, and”

AVITA Medical, Inc. reported Fourth Quarter 2023 results: revenue Commercial revenue increased approximately 50% to $14.1 million, EPS Net loss was $7.1 million, or a loss of $0.28 per basic and diluted share.

“reported financial results for the fourth quarter and full-year ended December 31, 2023. Fourth Quarter 2023 Financial Highlights • Commercial revenue increased approximately 50% to $14.1 million compared to the same period in 2022 • Gross profit margin of 87.3% Full-Year 2023 Financial Highlights • Commercial revenue increased approximately 46% to $49.8”

AVITA Medical, Inc. reported fourth quarter and full-year ended December 31, 2023 results: revenue Commercial revenue increased approximately 50% to $14.1 million, EPS loss of $0.28 per basic and diluted share.

“reported financial results for the fourth quarter and full-year ended December 31, 2023. Fourth Quarter 2023 Financial Highlights • Commercial revenue increased approximately 50% to $14.1 million compared to the same period in 2022 • Gross profit margin of 87.3% Full-Year 2023 Financial Highlights • Commercial revenue increased approximately 46% to $49.8”

AVITA Medical, Inc. reported first quarter and full-year 2024 results: revenue range of $14.8 to $15.6 million and $78.5 to $84.5 million. Guidance reaffirmed.

“committed to sustaining growth and building our business in 2024.” 2024 Financial Guidance • Commercial revenue for the first quarter 2024 is expected to be in the range of $14.8 to $15.6 million, reflecting growth at the lower bound of approximately 42% and upper bound of approximately 50% over the same period in the prior year • Commercial revenue for”

AVITA Medical, Inc. reported fourth quarter and full-year ended December 31, 2023 results: revenue approximately $14.1 million and approximately $49.8 million.

“its post-market study, TONE. Preliminary Fourth Quarter and Full-Year 2023 Financial Highlights • Commercial revenue for the fourth quarter 2023 is expected to be approximately $14.1 million, an increase of approximately 50% compared to same period in 2022 • Commercial revenue for the full-year 2023 is expected to be approximately $49.8 million, an increase of”

AVITA Medical, Inc. entered into Distribution Agreement with Stedical Scientific, Inc. valued at Exclusive distribution of PermeaDerm Biosynthetic Wound Matrix in the US; initial 5-year term with a (effective 2024-01-10).

“On January 10, 2024, AVITA Medical Americas LLC (“AVITA Americas”), a wholly-owned subsidiary of AVITA Medical, Inc., (the “Company”) entered into an exclusive multi-year distribution agreement (“Agreement”) with Stedical Scientific, Inc. (“Stedical Scientific”) to commercialize PermeaDerm® Biosynthetic Wound Matrix in the United States.”

AVITA Medical, Inc. reported the third quarter ended September 30, 2023 results: revenue $13.6 million, net income $8.7 million, EPS $0.34 per basic and diluted share. Guidance reaffirmed.

“$13.5 million in the three-months ended September 30, 2023, compared to $9.0 million in the same period in 2022. Total revenue, which includes BARDA revenue, increased by 50% to $13.6 million compared to $9.1 million in the same period in 2022. Gross profit margin increased by 1.3% to 84.5% compared to 83.2% for the third quarter of 2022. The increase was largely”

AVITA Medical, Inc. reported the quarter ended September 30, 2023 results: revenue $13.5 million. Guidance reaffirmed.

“preliminary commercial revenue was $13.5 million”

AVITA Medical, Inc. incurred credit facility of up to $90 million with an affiliate of OrbiMed at the greater of (x) the SOFR rate for such period and (y) 4.00% plus, in either c maturing five years.

“The Credit Agreement provides for a five-year senior secured credit facility in an aggregate principal amount of up to $90 million (the “Loan Facility"), of which (i) $40 million was made available on the Closing Date (the “Initial Commitment Amount")”

AVITA Medical, Inc. entered into Credit Agreement with an affiliate of OrbiMed valued at up to $90 million (effective 2023-10-18).

“AVITA Medical, Inc. (the “Company”) entered into a Credit Agreement (the “Credit Agreement”), by and between the Company, as borrower, and an affiliate of OrbiMed as the lender and administrative agent (the “Lender”). The Credit Agreement provides for a five-year senior secured credit facility in an aggregate principal amount of up to $90 million”

AVITA Medical, Inc. reported second quarter June 30, 2023 results: revenue $11.7 million, net income $10.4 million, EPS $0.41 per share. Guidance raised.

“Commercial revenue of $11.7 million, a 42% increase compared to $8.2 million for the same period in 2022”

David O'Toole was appointed as Chief Financial Officer at AVITA Medical, Inc..

“AVITA Medical, Inc. (the “Company”) entered into an Executive Employment Agreement (the “Agreement”) with David O’Toole with an effective date of June 15, 2023 (the “Effective Date”), pursuant to which Mr. O’Toole will serve as the Company’s Chief Financial Officer.”

AVITA Medical, Inc. shareholders approved Amendment of 2020 Omnibus Plan.

“12. Amendment of 2020 Omnibus Plan: Stockholders approved (a) the Plan Amendment by a vote of (i) 8,918,961 in favor, (ii) 1,337,019 against, (iii) 753,076 abstaining, and (iv) 2,118,249 broker non-votes.”

AVITA Medical, Inc. shareholders approved Issuance of Securities to Mr. James Corbett.

“11. Issuance of Securities to Mr. James Corbett: Stockholders approved the grant of options to acquire 100,000 shares of common stock of the Company (which may be represented by CDIs) to the Company’s Chief Executive Officer, Mr. James Corbett, on the terms and conditions set forth in the Proxy Statement by a vote of (i) 8,618,300 in favor, (ii) 1,575,435 against, (iii) 815,321 abstaining, and (iv) 2,118,249 broker non-votes.”

AVITA Medical, Inc. shareholders approved Issuance of Securities to Mr. Cary Vance.

“9. Issuance of Securities to Mr. Cary Vance: Stockholders approved the grant of restricted stock units equal in value to $147,000 (at the time of the grant) and the grant of stock options equal in value to $63,000 (at the time of the grant) to Mr. Cary Vance on the terms and conditions set out in the Proxy Statement in recognition of Mr. Vance being appointed as a new director of the Company during 2023, by a vote of (i) 8,634,362 in favor, (ii) 1,546,936 against, (iii) 827,758 abstaining, and (iv) 2,118,249 broker non-votes.”

AVITA Medical, Inc. shareholders approved Issuance of Securities to Mr. Robert McNamara.

“7. Issuance of Securities to Mr. Robert McNamara : Stockholders approved the grant of restricted stock units equal in value to $147,000 (at the time of the grant) and the grant of stock options equal in value to $63,000 (at the time of the grant) to Mr. Robert McNamara on the terms and conditions set out in the Proxy Statement in recognition of Mr. McNamara being appointed as a new director of the Company during 2023, by a vote of (i) 8,696,129 in favor, (ii) 1,507,847 against, (iii) 805,080 abstaining, and (iv) 2,118,249 broker non-votes.”

AVITA Medical, Inc. shareholders approved Issuance of Securities to Ms. Jan Stern Reed.

“6. Issuance of Securities to Ms. Jan Stern Reed : Stockholders approved the grant of restricted stock units equal in value to $87,500 (at the time of the grant) and the grant of stock options equal in value to $37,500 (at the time of the grant) to Ms. Jan Stern Reed on the terms and conditions set out in the Proxy Statement by a vote of (i) 8,895,165 in favor, (ii) 1,330,855 against, (iii) 783,036 abstaining, and (iv) 2,118,249 broker non-votes.”

AVITA Medical, Inc. shareholders approved Issuance of Securities to Mr. Jeremy Curnock Cook.

“5. Issuance of Securities to Mr. Jeremy Curnock Cook : Stockholders approved the grant of restricted stock units equal in value to $87,500 (at the time of the grant) and the grant of stock options equal in value to $37,500 (at the time of the grant) to Mr. Jeremy Curnock Cook on the terms and conditions set out in the Proxy Statement by a vote of (i) 8,877,076 in favor, (ii) 1,352,935 against, (iii) 779,045 abstaining, and (iv) 2,118,249 broker non-votes.”

AVITA Medical, Inc. shareholders approved Issuance of Securities to Professor Suzanne Crowe.

“4. Issuance of Securities to Professor Suzanne Crowe : Stockholders approved the grant of restricted stock units equal in value to $87,500 (at the time of the grant) and the grant of stock options equal in value to $37,500 (at the time of the grant) to Professor Suzanne Crowe on the terms and conditions set out in the Proxy Statement by a vote of (i) 8,931,133 in favor, (ii) 1,323,484 against, (iii) 754,439 abstaining, and (iv) 2,118,249 broker non-votes.”

AVITA Medical, Inc. shareholders approved Issuance of Securities to Mr. Louis Panaccio.

“3. Issuance of Securities to Mr. Louis Panaccio : Stockholders approved the grant of restricted stock units equal in value to $87,500 (at the time of the grant) and the grant of stock options equal in value to $37,500 (at the time of the grant) to Mr. Lou Panaccio on the terms and conditions set out in the Proxy Statement by a vote of (i) 8,895,435 in favor, (ii) 1,347,898 against, (iii) 765,723 abstaining, and (iv) 2,118,249 broker non-votes.”

AVITA Medical, Inc. shareholders approved Appointment of Independent Auditor at the 2023-12-31 meeting.

“2. Appointment of Independent Auditor . The appointment of Grant Thornton LLP as the Company’s independent public accountants for the fiscal year ending December 31, 2023 was ratified by a vote of (i) 12,509,340 in favor, (ii) 83,447 against, and (iii) 534,518 abstaining. The Company did not receive any broker non-votes with respect to such proposal.”

AVITA Medical, Inc. shareholders approved Election of Directors.

“1. Election of Directors . All seven directors named in the Proxy Statement were elected to serve on the Company’s Board of Directors with the following vote: Name Votes For Votes Withheld Broker Non-Votes Louis Panaccio 9,435,124 1,573,932 2,118,249 James Corbett 10,042,656 966,400 2,118,249 Jeremy Curnock Cook 10,066,927 942,129 2,118,249 Professor Suzanne Crowe 10,173,257 835,799 2,118,249 Jan Stern Reed 9,785,570 1,223,486 2,118,249 Robert McNamara 10,205,699 803,357 2,118,249 Cary Vance 10,201,085 807,971 2,118,249”

AVITA Medical, Inc. reported fiscal quarter ended March 31, 2023 results: revenue $10.6 million, net income $9.2 million, EPS $0.37 per share.

“Item 2.02. Results of Operations and Financial Condition. On May 12, 2023, AVITA Medical, Inc. (the “Company”) furnished a Current Report on Form 8-K (the “Original Form 8-K”) with a transcript of the Company’s May 11, 2023 conference call discussing the Company’s financial results for its fiscal quarter ended March 31, 2023 as Exhibit 99.2. Exhibit 99.2 to the Original Form 8-K inadvertently included extraneous tabular information from S&P Global Market Intelligence, including financial results and consensus data for the quarter ended March 31, 2023 in Australian Dollars. The Company’s actual results are reported in U.S. Dollars and included $10.6 million in revenue and a net loss of $9.2 million, or $0.37 per share.”

AVITA Medical, Inc. reported the fiscal quarter ended March 31, 2023 results: revenue $10.6 million, net income $9.2 million, EPS $0.37 per share. Guidance reaffirmed.

“Total revenue, which includes BARDA revenue, increased by 40% to $10.6 million compared to $7.5 million in the same period in 2022. The gross profit margin was increased by 8% to 84% compared to 76% for the first quarter of 2022. Total operating expenses for the quarter increased by 22% to $19.4 million, compared to $16.0 million in the same period in 2022, primarily due to increased field expansion and continued development of the RECELL GO device for the planned submission in June 2023. Net loss decreased by 3% to $9.2 million, or $0.37 per share, compared to a net loss of $9.5 million, or $0.38 per share, in the same period in 2022.”

Erin Liberto resigned as Chief Commercial Officer at AVITA Medical, Inc..

“Effective May 11, 2023, Ms. Erin Liberto, the Company’s Chief Commercial Officer, resigned from her position and accepted a role with a privately held, non-competitive business.”

Robert McNamara was appointed as Board of Directors at AVITA Medical, Inc..

“On March 23, 2023, AVITA Medical, Inc. (the “Company”) issued a press release announcing the appointment of Robert McNamara to its Board of Directors (the “Board”), effective April 1, 2023”

Cary Vance was appointed as Director at AVITA Medical, Inc..

“On March 16, 2023, AVITA Medical, Inc. (the “Company”) issued a press release announcing the appointment of Cary Vance to its Board of Directors (the “Board”), effective April 1, 2023”